EN DE
Watch Climb Bio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Climb Bio Inc (CLYM) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Climb Bio Inc stock $7.69, price $9.94, that is 22.6% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US28658R1068

CB Climb Bio Inc logo Thin data Nov 17, 2026

Climb Bio Inc

CLYM · US

Expensive (fair value 23% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Insiders sold $1.8M (6M) 
Fair value $7.69 · Overvalued 
Quality 37/100 
Negative free cash flow 
Trails peers (1/6) 
Narrow moat 9/100 · thin data
Thin data 
Estimate
Watch Climb Bio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$28.61 $1.13 Fair Value $7.69 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $1.13 – $28.61 · fair‑value band $5.77 – $9.61 · the $9.94 price screens above the $7.69 fair value. As of Nov 17, 2026.

Follow Climb Bio in your weekly email

Every Wednesday you see whether Climb Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

Show moreShow less

It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.

In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases.

The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Stock analysis

Climb Bio Inc (CLYM) currently trades at $9.94, while our estimate is $7.69, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.77 (bear) to $9.61 (bull), the price of $9.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Climb Bio Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$59.9M in FY2025.

Key figures

Market cap $757M Small · EPS (TTM) $−0.8700 · Return on equity −29.3% · Return on assets (EBIT) −33.7% (5-year average) · Free cash flow −$54.5M · Net cash $35.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 506% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −23%, CLYM screens richer than that median.

Fair Value

Bear $5.77 Fair Value $7.69 Bull $9.61
Price $9.94 · Downside -22.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 62
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 46
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 76
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $1.8M and none bought.

  • SaleStephen Basil ThomasDirector3× since Feb 12, 2026: 250,000 shares, avg. $8.98$2.2MSep 15, 202610b5-1 plan
  • SaleAoife BrennanPresident and CEO, Director30,902 shares at $13.17$406,979Jun 29, 202610b5-1 plan
  • BuyRA Capital Healthcare Fund LPDirector, 10% owner7,111 shares at $3.50$24,889Jan 5, 2026
  • BuyPeter KolchinskyDirector, 10% owner314,561 shares at $2.40$754,737Dec 12, 2025

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CLYM screens overvalued: fair value 23% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Climb Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −22.6% · Above median
Profitability
Return on assets −35.7% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.72× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs CLYM
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs CLYM
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs CLYM
argenx SE ARGX $950.95 $908.40 −4% vs CLYM
CSL Limited CSL A$199.55 A$186.49 −7% vs CLYM
Moderna, Inc MRNA $215.27 $135.64 −37% vs CLYM
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs CLYM
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs CLYM
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs CLYM
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs CLYM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Climb Bio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Climb Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/CLYM

Frequently asked questions

Is Climb Bio Inc (CLYM) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $7.69 versus a price of $9.94, about 23% lower (overvalued).
What is the fair value of CLYM?
Our estimate for Climb Bio Inc is $7.69 (as of Nov 17, 2026), built from audited fundamentals. The current price: $9.94.
What is the quality score of CLYM?
Climb Bio Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Climb Bio Inc (CLYM)?
Our calculated price target is the estimate of $7.69 (as of Nov 17, 2026). Cautious scenario $5.77, optimistic scenario $9.61. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Climb Bio Inc stock forecast for 2026?
Our estimate puts fair value at $7.69, about 23% lower versus a price of $9.94 (overvalued). Cautious scenario $5.77, optimistic scenario $9.61. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Climb Bio Inc (CLYM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Climb Bio Inc it is $7.69 per share (as of Nov 17, 2026), against a price of $9.94.
Is Climb Bio Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, CLYM trades above its calculated fair value: price $9.94, fair value $7.69, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLYM?
No. The price is what the market pays today ($9.94); the fair value is what the company's own numbers justify ($7.69). For Climb Bio Inc the two are $2.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is Climb Bio Inc worth?
The market values Climb Bio Inc at about $757M (market capitalisation, as of Nov 17, 2026). Per share that is $9.94; our models calculate a fair value of $7.69 per share.
What do the bullish and bearish scenarios say about CLYM?
Our models span a range for Climb Bio Inc: cautious scenario $5.77, base $7.69, optimistic $9.61 per share (as of Nov 17, 2026, price $9.94). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Climb Bio Inc (CLYM)?
Balance-sheet figures for Climb Bio Inc (as of Nov 17, 2026): return on equity −29.3%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is CLYM from its 52-week high?
Climb Bio Inc trades at $9.94, about 44% below its 52-week high of $17.84 and 506% above the low of $1.64 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $7.69 is for.
Which stocks are comparable to Climb Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Climb Bio Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $9.94, calculated fair value $7.69 (−23%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Climb Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Climb Bio Inc (CLYM)?
The closing price on Nov 16, 2026 was $9.94. Our estimate is $7.69, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Climb Bio Inc right now?
The price sits above even our optimistic bull case ($9.61). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Climb Bio Inc

How large is the market capitalisation of Climb Bio Inc (CLYM)?
The market capitalisation of Climb Bio Inc is $757M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Climb Bio Inc (CLYM)?
Earnings per share at Climb Bio Inc are $−0.8700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Climb Bio Inc (CLYM)?
The return on equity (ROE) of Climb Bio Inc is −29.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Climb Bio Inc (CLYM)?
On an EBIT basis the return on assets of Climb Bio Inc is −33.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Climb Bio Inc (CLYM) generate?
The free cash flow of Climb Bio Inc is −$54.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Climb Bio Inc (CLYM) hold?
Climb Bio Inc holds more cash than debt, $35.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Climb Bio Inc in the live analysis

One click puts Climb Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.